These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
429 related articles for article (PubMed ID: 34849667)
1. Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines. Foltran D; Delmas C; Flumian C; De Paoli P; Salvo F; Gautier S; Drici MD; Karsenty C; Montastruc F Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):99-103. PubMed ID: 34849667 [TBL] [Abstract][Full Text] [Related]
2. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada. Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115 [TBL] [Abstract][Full Text] [Related]
3. Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study. Chen C; Chen C; Cao L; Fang J; Xiao J Int Immunopharmacol; 2024 May; 133():112022. PubMed ID: 38615382 [TBL] [Abstract][Full Text] [Related]
4. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review. Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976 [TBL] [Abstract][Full Text] [Related]
5. Postmarketing active surveillance of myocarditis and pericarditis following vaccination with COVID-19 mRNA vaccines in persons aged 12 to 39 years in Italy: A multi-database, self-controlled case series study. Massari M; Spila Alegiani S; Morciano C; Spuri M; Marchione P; Felicetti P; Belleudi V; Poggi FR; Lazzeretti M; Ercolanoni M; Clagnan E; Bovo E; Trifirò G; Moretti U; Monaco G; Leoni O; Da Cas R; Petronzelli F; Tartaglia L; Mores N; Zanoni G; Rossi P; Samez S; Zappetti C; Marra AR; Menniti Ippolito F; PLoS Med; 2022 Jul; 19(7):e1004056. PubMed ID: 35900992 [TBL] [Abstract][Full Text] [Related]
6. Booster dose of COVID-19 mRNA vaccine does not increase risks of myocarditis and pericarditis compared with primary vaccination: New insights from the vaccine adverse event reporting system. Chen C; Fu F; Ding L; Fang J; Xiao J Front Immunol; 2022; 13():938322. PubMed ID: 36172346 [TBL] [Abstract][Full Text] [Related]
7. Pericarditis and myocarditis after COVID-19 mRNA vaccination in a nationwide setting. Yap J; Tham MY; Poh J; Toh D; Chan CL; Lim TW; Lim SL; Chia YW; Lim YT; Choo J; Ding ZP; Foo LL; Kuo S; Lau YH; Lee A; Yeo KK Ann Acad Med Singap; 2022 Feb; 51(2):96-100. PubMed ID: 35224605 [TBL] [Abstract][Full Text] [Related]
8. Adverse Events Following COVID-19 Vaccination in Adolescents: Insights From Pharmacovigilance Study of VigiBase. Kim DH; Kim JH; Oh IS; Choe YJ; Choe SA; Shin JY J Korean Med Sci; 2024 Mar; 39(8):e76. PubMed ID: 38442719 [TBL] [Abstract][Full Text] [Related]
9. Global estimates on the reports of vaccine-associated myocarditis and pericarditis from 1969 to 2023: Findings with critical reanalysis from the WHO pharmacovigilance database. Lee S; Jo H; Lee H; Lee H; Lee J; Kim HJ; Kang J; Jacob L; Smith L; Rahmati M; López Sánchez GF; Dragioti E; Jeon H; Cho JM; Choi Y; Park J; Woo S; Yon DK J Med Virol; 2024 Jun; 96(6):e29693. PubMed ID: 38859751 [TBL] [Abstract][Full Text] [Related]
10. Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination - PCORnet, United States, January 2021-January 2022. Block JP; Boehmer TK; Forrest CB; Carton TW; Lee GM; Ajani UA; Christakis DA; Cowell LG; Draper C; Ghildayal N; Harris AM; Kappelman MD; Ko JY; Mayer KH; Nagavedu K; Oster ME; Paranjape A; Puro J; Ritchey MD; Shay DK; Thacker D; Gundlapalli AV MMWR Morb Mortal Wkly Rep; 2022 Apr; 71(14):517-523. PubMed ID: 35389977 [TBL] [Abstract][Full Text] [Related]
11. Risk of myocarditis and pericarditis following coronavirus disease 2019 messenger RNA Vaccination-A nationwide study. Su WJ; Liu YL; Chang CH; Lin YC; Huang WI; Wu LC; Chen SF; Lin YS; Hsieh YL; Yang CA; Lin CH; Chan KA; Lee PI; Chuang JH; Yang CH J Microbiol Immunol Infect; 2023 Jun; 56(3):558-565. PubMed ID: 36804307 [TBL] [Abstract][Full Text] [Related]
12. Myocarditis or Pericarditis Events After BNT162b2 Vaccination in Individuals Aged 12 to 17 Years in Ontario, Canada. Buchan SA; Alley S; Seo CY; Johnson C; Kwong JC; Nasreen S; Thampi N; Lu D; Harris TM; Calzavara A; Wilson SE JAMA Pediatr; 2023 Apr; 177(4):410-418. PubMed ID: 36848096 [TBL] [Abstract][Full Text] [Related]
13. Reports of myocarditis and pericarditis following mRNA COVID-19 vaccination: a systematic review of spontaneously reported data from the UK, Europe and the USA and of the scientific literature. Lane S; Yeomans A; Shakir S BMJ Open; 2022 May; 12(5):e059223. PubMed ID: 35613761 [TBL] [Abstract][Full Text] [Related]
14. Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level. Chouchana L; Blet A; Al-Khalaf M; Kafil TS; Nair G; Robblee J; Drici MD; Valnet-Rabier MB; Micallef J; Salvo F; Treluyer JM; Liu PP Clin Pharmacol Ther; 2022 Mar; 111(3):605-613. PubMed ID: 34860360 [TBL] [Abstract][Full Text] [Related]
15. Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. Chua GT; Kwan MYW; Chui CSL; Smith RD; Cheung ECL; Ma T; Leung MTY; Tsao SSL; Kan E; Ng WKC; Chan VCM; Tai SM; Yu TC; Lee KP; Wong JSC; Lin YK; Shek CC; Leung ASY; Chow CK; Li KW; Ma J; Fung WY; Lee D; Ng MY; Wong WHS; Tsang HW; Kwok J; Leung D; Chung KL; Chow CB; Chan GCF; Leung WH; To KKW; Yuen KY; Lau YL; Wong ICK; Ip P Clin Infect Dis; 2022 Sep; 75(4):673-681. PubMed ID: 34849657 [TBL] [Abstract][Full Text] [Related]
16. Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA COVID-19 vaccines in Europe and the United States. Hatziantoniou S; Anastassopoulou C; Lazaros G; Vasileiou K; Tsioufis C; Tsakris A Expert Rev Vaccines; 2022 Nov; 21(11):1691-1696. PubMed ID: 35815358 [TBL] [Abstract][Full Text] [Related]
17. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines. Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537 [TBL] [Abstract][Full Text] [Related]
18. Risk of myocarditis and pericarditis in mRNA COVID-19-vaccinated and unvaccinated populations: a systematic review and meta-analysis. Alami A; Krewski D; Farhat N; Mattison D; Wilson K; Gravel CA; Farrell PJ; Crispo JAG; Haddad N; Perez-Lloret S; Villeneuve PJ BMJ Open; 2023 Jun; 13(6):e065687. PubMed ID: 37339840 [TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. Husby A; Hansen JV; Fosbøl E; Thiesson EM; Madsen M; Thomsen RW; Sørensen HT; Andersen M; Wohlfahrt J; Gislason G; Torp-Pedersen C; Køber L; Hviid A BMJ; 2021 Dec; 375():e068665. PubMed ID: 34916207 [TBL] [Abstract][Full Text] [Related]
20. Comparative Risk of Myocarditis/Pericarditis Following Second Doses of BNT162b2 and mRNA-1273 Coronavirus Vaccines. Naveed Z; Li J; Wilton J; Spencer M; Naus M; Velásquez García HA; Kwong JC; Rose C; Otterstatter M; Janjua NZ; J Am Coll Cardiol; 2022 Nov; 80(20):1900-1908. PubMed ID: 36357091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]